Kraig Biocraft Opens New Biotech Research and Production Center
The biotechnology company has officially opened its new Michigan research and production center for the production of spider silk-based fibers, as well as for the company’s polymer research and development program.
On Oct. 23, 2017, Kraig Biocraft Laboratories, a developer of spider silk-based fibers, announced that its previously announced research and production facility in Michigan is now operational. The new facility will enable the domestic production of the spider silk-based fibers, centralize the company’s research and development program for new polymers, and facilitate relocated production operations from Indiana.
Over the next sixty days following this announcement, the company plans to expand the new facility’s production. Additionally, three separate strains of hatching and rearing of silkworms have begun at the site.
According to the company, the opening of the center will be followed by efforts to establish production centers in three overseas locations. During October 2017, the company’s management team is scheduled to meet with senior central government officials in Hanoi, Vietnam, to discuss this production venture. The company is also in communication with another silk-producing country to scale-up its spider silk technology.
Source: Kraig Biocraft Laboratories
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
